Chinese respiratory disease-focused pharmaceutical company CF PharmTech, Inc on Thursday said it has raised 360 million yuan ($50 million) in a Series F round of financing from healthcare-focused BioTrack Capital, CICC Capital’s CICC Qichen, CICC Qide, SAIC Hengxu, GP M&A Fund and Watson Investment.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
